Browse Technologies
Browse Technologies
Technology Keyword Search
Oncology
Search Results
Displaying: 11 - 20 of 21 Results
Mass spectrometry-based in vitro kinome activity assay
This technology is a new generation, high-throughput assay to quantitatively assess the activity of the kinome in a variety of samples. Cocktails of synthetic peptides are combined with a sample of interest and phosphorylated by kinases in the…
DBD
- Grant Zimmermann
Investigators
- Steven Gygi
- Judit Villen
- Kazuishi Kubota
- Yong Yu
Potent OGT inhibitors for the treatment of cancer and diabetic complications
First-in-class and potent OGT inhibitors The Walker group has developed novel high throughput assays (HTS) and screened 200,000 compounds at the Institute for Chemistry and Cell Biology (ICCB) at Harvard Medical School, and identified several…
DBD
- Vivian Berlin
Investigators
- Suzanne Walker Kahne
- Michael Lazarus
- Benjamin Gross
Knockout mouse model for human liver cancer
While most hepatocytes in healthy liver are resting cells, deletion of Mad2 in liver activates the cell cycles and causes proliferation of hepatocytes. Cre-mediated, simultaneous liver-specific knockout of Mad2 and p53 induces mouse cancer which…
DBD
- Grant Zimmermann
Investigators
- Peter Sorger
- Ying Yue
Trioxacarcins and analogs: DNA-modifying compounds with potent anti-proliferative effects
The trioxacarcins are a new class of DNA-modifying natural products with potent antiproliferative effects (with subnanmolar IC70 values against lung, mammary, and CNS cancer cell lines). Trioxacarcin A, B, and C were first discovered and isolated…
DBD
- Yelena Bisharyan
Investigators
- Andrew Myers
- Jakub Svenda
- Nicholas Hill
- Robert Yu
- Daniel Smaltz
- Thomas Magauer
Small-molecule macrocycles: Potent and selective Src kinase inhibitors
Macrocyclic compounds have unique properties that allow them to cover regions of chemical space not addressed by other small-molecule structural classes. By performing an in vitro selection screen of a broad untargeted DNA-encoded library of 13,824…
DBD
- Irit Ben-Chelouche
Investigators
- David Liu
- Ralph Kleiner
Fzd2 - novel anti-cancer therapeutic target
The role of β-catenin accumulation in the development of tumorigenicity has been well documented to date, with various mutations in β-catenin, APC, and axin genes typically to blame. Although β-catenin accumulation plays a role in hepatocellular…
DBD
- Irit Ben-Chelouche
Investigators
- Gavin MacBeath
- Taran Gujral
Controlled delivery of TLR agonists in structural polymeric devices
Scientist at the Mooney lab demonstrated that three different types of pathogens could be incorporated to act as adjuvant in cancer vaccines. They have successfully incorporated three Toll-like receptor agonists (TLR) within a structural polymeric…
Investigators
- David Mooney
- Omar Ali
- Glenn Dranoff
Continuous Evolution (PACE) of Botulinum Neurotoxins with Reprogrammed Substrate Specificity for Intracellular Protease Therapy
Biomacromolecule-based therapies are of keen interest to the pharmaceutical industry because macromolecules engage in highly specific interactions in biological systems compared to traditional small molecules. Despite their success, macromolecular…
DBD
- Irit Ben-Chelouche
Investigators
- David Liu
RGMb-deficient T cells for overcoming resistance to immune checkpoint blockade
Immune checkpoint blockade therapies targeting PD-1 or PD-L1 have been approved for more than 25 different tumors. However, many patients do not respond to PD-1/PD-L1 checkpoint blockade. The Sharpe lab at Harvard Medical School has identified that…
DBD
- Grant Zimmermann
Investigators
- Arlene Sharpe
- Dennis Kasper
PD-L2 modulated dendritic cells for cancer immunotherapy
Immune checkpoint blockade therapies targeting PD-1 or PD-L1 have been approved for more than 25 different tumors. However, many patients do not respond to PD-1/PD-L1 checkpoint blockade. The Sharpe lab has identified that dendritic cells (DCs) with…
DBD
- Grant Zimmermann
Investigators
- Arlene Sharpe
- Dennis Kasper